Chang Fangfang, Hu Xiaoshu, Wen Yiyang, Li Ping, Huangfu Yun, Zhang Fengjuan, Tan Jing, Cao Xuexia
（ 451191） Department of Internal Medicine, Henan Medical College, Zhengzhou 451191, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 Sep 20;55(5):1247-1253. doi: 10.12182/20240960207.
To examine the relationship between the expressions of mismatch repair proteins, MutS homolog 2 (MSH2) and MutS homolog 6 (MSH6), and villin and the pathological features in patients with colon cancer.
A total of 310 cases of colon cancer patients who were treated at our hospital between January 2017 and September 2021 were selected. The diagnosis of colon cancer of all patients was verified by pathological evaluation. Immunohistochemistry was used to determine the protein expressions of MSH2, MSH6, and villin. The correlation between the expressions of MSH2, MSH6, and villin and the clinicopathological parameters in patients with colon cancer was analyzed accordingly. Multivariate logistic regression was used to analyze the correlation between the expressions of MSH2, MSH6, and villin and the clinicopathological parameters of colon cancer. Kaplan-Meier survival curve was used to compare the 2-year survival rates of colon cancer patients with different expression levels of the proteins.
Among the 310 patients with colon cancer, the negative expression rates of MSH2, MSH6, and villin proteins in cancer tissues were 8.71% (27/310), 9.35% (29/310), and 46.13% (143/310), respectively. The negative expression rates of the three proteins in tissues adjacent to cancer were 3.23% (10/310), 4.19% (13/310), and 9.68% (30/310), respectively. The negative expression rates of the three proteins in cancer tissues were all higher than those in adjacent tissues (<0.05). Regression analysis showed that the expression of MSH2 and MSH6 in cancer tissues was correlated with the age, the location of tumor lesions, tumor differentiation degree, and lymph node metastasis in colon cancer patients (<0.05). The expression of villin in the cancer tissue is correlated with the depth of tumor infiltration, lymph node metastasis, distant metastasis, and clinical staging status in colon cancer patients (<0.05). The 2-year survival rates of patients with negative expressions of MSH2 and MSH6 were 51.85% and 44.83%, respectively, which were lower than those of patients with positive expression of MSH2 and MSH6 (79.51% and 80.43%, <0.05). Thirteen patients (4.1%) had negative expression of MSH2, MSH6, and villin (referred to as "triple negative expressions") in the cancer tissues, and their 2-year survival rate was 30.77%, which was lower than that of colon cancer patients who did not meet the criteria for triple negative expressions (79.12% [235/297], <0.05).
The expressions of MSH2, MSH6, and villin are closely correlated with the pathological features of colon cancer patients. Evaluating the expression of the three proteins may assist in the clinical diagnosis, treatment, and prognosis evaluation of colon cancer.
探讨错配修复蛋白MutS同源物2（MSH2）、MutS同源物6（MSH6）和绒毛蛋白的表达与结肠癌患者病理特征之间的关系。
选取2017年1月至2021年9月在我院接受治疗的310例结肠癌患者。所有患者的结肠癌诊断均经病理评估证实。采用免疫组织化学法检测MSH2、MSH6和绒毛蛋白的表达。分析MSH2、MSH6和绒毛蛋白表达与结肠癌患者临床病理参数之间的相关性。采用多因素logistic回归分析MSH2、MSH6和绒毛蛋白表达与结肠癌临床病理参数的相关性。采用Kaplan-Meier生存曲线比较不同蛋白表达水平的结肠癌患者的2年生存率。
310例结肠癌患者中，癌组织中MSH2、MSH6和绒毛蛋白的阴性表达率分别为8.71%（27/310）、9.35%（29/310）和46.13%（143/310）。癌旁组织中这三种蛋白的阴性表达率分别为3.23%（10/310）、4.19%（13/310）和9.68%（30/310）。癌组织中这三种蛋白的阴性表达率均高于癌旁组织（<0.05）。回归分析显示，癌组织中MSH2和MSH6的表达与结肠癌患者的年龄、肿瘤病变部位、肿瘤分化程度及淋巴结转移相关（<0.05）。癌组织中绒毛蛋白的表达与结肠癌患者的肿瘤浸润深度、淋巴结转移、远处转移及临床分期相关（<0.05）。MSH2和MSH6阴性表达患者的2年生存率分别为51.85%和44.83%，低于MSH2和MSH6阳性表达患者（79.51%和80.43%，<0.05）。13例（4.1%）患者癌组织中MSH2、MSH6和绒毛蛋白呈阴性表达（称为“三阴性表达”），其2年生存率为30.77%，低于不符合三阴性表达标准的结肠癌患者（79.12%[235/297]，<0.05）。
MSH2、MSH6和绒毛蛋白的表达与结肠癌患者的病理特征密切相关。评估这三种蛋白的表达可能有助于结肠癌的临床诊断、治疗及预后评估。
